CIT:GETTEXCintas Corporation Analysis
Data as of 2026-03-15 - not real-time
$105.69
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical snapshot: Citigroup’s stock is trading at $105.69, which lies below the 20‑day SMA of $110.92 and the 50‑day SMA of $114.79, yet remains above the 200‑day SMA of $100.75, indicating a short‑term pullback within a longer‑term uptrend. The RSI of 38.9 hints at a modest oversold condition, while the MACD line sits beneath its signal, flagging bearish momentum. Current price is perched near the identified support at $102.01 with resistance around $117.04, and the stock is experiencing elevated 30‑day volatility of 41% and a beta of 1.27, underscoring heightened market sensitivity.
Fundamental outlook: Valuation appears attractive, with a trailing P/E of 15.1 versus the industry average of 16.35 and a forward P/E of 8.7, suggesting significant upside potential. The dividend yield of 2.27% and a modest payout ratio of 33% support a sustainable income stream, bolstered by a massive cash pile of $989 B against $777 B of debt. Although operating cash flow is negative, analysts collectively rate the stock as a Buy with a median target of $134.5, implying a 27% upside, and the prevailing market sentiment leans toward “Greed.”
Fundamental outlook: Valuation appears attractive, with a trailing P/E of 15.1 versus the industry average of 16.35 and a forward P/E of 8.7, suggesting significant upside potential. The dividend yield of 2.27% and a modest payout ratio of 33% support a sustainable income stream, bolstered by a massive cash pile of $989 B against $777 B of debt. Although operating cash flow is negative, analysts collectively rate the stock as a Buy with a median target of $134.5, implying a 27% upside, and the prevailing market sentiment leans toward “Greed.”
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price testing near $102 support
- bearish MACD alignment
- RSI approaching oversold territory
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- valuation gap vs industry peers
- robust dividend yield and payout ratio
- analyst consensus buy with strong upside target
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- sustained upside potential to $134 median target
- global diversification across major markets
- stable dividend income supporting total return
Key Metrics & Analysis
Financial Health
Revenue Growth4.40%
Profit Margin18.89%
P/E Ratio15.1
ROE6.83%
ROA0.58%
P/B Ratio1.0
Op. Cash Flow$-67632001024
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI38.9
Support$102.01
Resistance$117.04
MA 20$110.92
MA 50$114.79
MA 200$100.75
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Target Price$134.32
Upside/Downside27.09%
GradeUndervalued
TypeBlend
Dividend Yield2.27%
Risk Assessment
Beta1.27
Volatility41.25%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.